Clinical Utility and Economic Impact of CYP2D6 Genotyping
- PMID: 27514466
- DOI: 10.1016/j.cll.2016.05.008
Clinical Utility and Economic Impact of CYP2D6 Genotyping
Abstract
Pharmacogenetics examines an individual's genetic makeup to help predict the safety and efficacy of medications. Practical application optimizes treatment selection to decrease the failure rate of medications and improve clinical outcomes. Lack of efficacy is costly due to adverse drug reactions and increased hospital stays. Cytochrome P450 2D6 (CYP2D6) metabolizes roughly 25% of all drugs. Detecting variants that cause altered CYP2D6 enzymatic activity identifies patients at risk of adverse drug reactions or therapeutic failure with standard dosages of medications metabolized by CYP2D6. This article discusses the clinical application of pharmacogenetics to improve care and decrease costs.
Keywords: CYP2D6; CYP2D6 genotyping; Pharmacoeconomics; Pharmacogenetics.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication.Psychiatry Res. 2019 Sep;279:111-115. doi: 10.1016/j.psychres.2018.02.055. Epub 2018 Mar 9. Psychiatry Res. 2019. PMID: 29699889
-
CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.Pharmacogenomics. 2009 Apr;10(4):685-99. doi: 10.2217/pgs.09.15. Pharmacogenomics. 2009. PMID: 19374522
-
Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?Psychiatry Res. 2019 Jan;271:604-613. doi: 10.1016/j.psychres.2018.12.053. Epub 2018 Dec 8. Psychiatry Res. 2019. PMID: 30554109 Review.
-
Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.Ann Pharmacother. 2007 Mar;41(3):408-13. doi: 10.1345/aph.1H482. Epub 2007 Mar 6. Ann Pharmacother. 2007. PMID: 17341534
-
Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization.Curr Drug Metab. 2014 Feb;15(2):218-32. doi: 10.2174/1389200215666140202215316. Curr Drug Metab. 2014. PMID: 24524666 Review.
Cited by
-
The Role of Genetic Polymorphisms in Chronic Pain Patients.Int J Mol Sci. 2018 Jun 8;19(6):1707. doi: 10.3390/ijms19061707. Int J Mol Sci. 2018. PMID: 29890676 Free PMC article. Review.
-
Abundance of Cytochromes in Hepatic Extracellular Vesicles Is Altered by Drugs Related With Drug-Induced Liver Injury.Hepatol Commun. 2018 Aug 23;2(9):1064-1079. doi: 10.1002/hep4.1210. eCollection 2018 Sep. Hepatol Commun. 2018. PMID: 30202821 Free PMC article.
-
Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.Int J Mol Sci. 2021 Dec 10;22(24):13302. doi: 10.3390/ijms222413302. Int J Mol Sci. 2021. PMID: 34948113 Free PMC article. Review.
-
Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study.Drugs Real World Outcomes. 2020 Mar;7(1):63-73. doi: 10.1007/s40801-019-00177-4. Drugs Real World Outcomes. 2020. PMID: 31863305 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
